Company intelligence / Profile preview
Novo Nordisk
Bagsværd, Denmarknovonordisk.com ↗
- Ownership
- Public · NVO
- Development stage
- Other
01
Overview
Novo Nordisk has multiple commercial products including Ozempic and Wegovy (semaglutide) for diabetes and weight management, which have shown significant efficacy in weight loss and cardiovascular risk reduction. Their GLP-1 drugs have demonstrated superior weight loss compared to previous treatments[9].
- Therapeutic areas
- HematologyEndocrinology
- Modalities
- Biological medicinesinsulinGLP-1 agonistspeptides
- Industry
- Pharma
02
Drug pipeline
205 assets204 more assets in the full pipeline.
03
Partnerships
UNICEF (partnership to tackle childhood obesity)[8]Flagship Pioneering (framework collaboration to advance breakthrough medicines in cardiometabolic diseases)[10]Omega Therapeutics and Cellarity (research collaborations)[10]
04
Financials
- Market cap
- $177.7B
- Total revenue
- $46.2B
- Enterprise value
- $190.4B
Beyond the preview
Go deeper on Novo Nordisk.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novo Nordisk.